Literature DB >> 15475735

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

Kerri A Schoedel1, Ewa B Hoffmann, Yushu Rao, Edward M Sellers, Rachel F Tyndale.   

Abstract

Genetically variable CYP2A6 is the primary enzyme that inactivates nicotine to cotinine. Our objective was to investigate allele frequencies among five ethnic groups and to investigate the relationship between genetically slow nicotine metabolic inactivation and smoking status, cigarette consumption, age of first smoking and duration of smoking. Chinese, Japanese, Canadian Native Indian, African-North American and Caucasian DNA samples were assessed for CYP2A6 allelic frequencies (CYP2A6*1B-*12,*1x2). Adult Caucasian non-smokers (n = 224) (1-99 cigarettes/lifetime) and smokers (n = 375) (> or = 100 cigarettes/lifetime) were assessed for demographics, tobacco/drug use history and DSM-IV dependence and genotyped for CYP2A6 alleles associated with decreased nicotine metabolism (CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12). CYP2A6 allele frequencies varied substantially among the ethnic groups. The proportion of Caucasian slow nicotine inactivators was significantly lower in current, DSM-IV dependent smokers compared to non-smokers [7.0% and 12.5%, respectively, P = 0.03, odds ratio (OR) = 0.52; 95% confidence interval (CI) 0.29-0.95]; non-dependent smokers showed similar results. Daily cigarette consumption (cigarettes/day) was significantly (P = 0.003) lower for slow (21.3; 95% CI 17.4-25.2) compared to normal inactivators (28.2; 95% CI 26.4-29.9); this was observed only in DSM-IV dependent smokers. Slow inactivators had a significantly (P = 0.03) lower age of first smoking compared to normal inactivators (13.0 years of age; 95% CI 12.1-14.0 versus 14.2; 95% CI 13.8-14.6), and a trend towards smoking for a shorter duration. This study demonstrates that slow nicotine inactivators are less likely to be adult smokers (dependent or non-dependent). Slow inactivators also smoked fewer cigarettes per day and had an earlier age of first smoking (only dependent smokers).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475735     DOI: 10.1097/00008571-200409000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  120 in total

Review 1.  Is there evidence for potential harm of electronic cigarette use in pregnancy?

Authors:  Melissa A Suter; Joan Mastrobattista; Maike Sachs; Kjersti Aagaard
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-11-04

2.  Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers.

Authors:  Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Xue-Qing Yu; Wei Chen; Qian Zhou; Wei-Qing Chen
Journal:  Ann Behav Med       Date:  2012-04

3.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

4.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

5.  CYP2A6 genetic variation and dexmedetomidine disposition.

Authors:  Utkarsh Kohli; Pratik Pandharipande; Mordechai Muszkat; Gbenga G Sofowora; Eitan A Friedman; Mika Scheinin; Alastair J J Wood; E Wesley Ely; Rachel F Tyndale; Leena Choi; C Michael Stein; Daniel Kurnik
Journal:  Eur J Clin Pharmacol       Date:  2012-01-21       Impact factor: 2.953

6.  Superior methadone treatment outcome in Hmong compared with non-Hmong patients.

Authors:  Gavin Bart; Qi Wang; James S Hodges; Chris Nolan; Gregory Carlson
Journal:  J Subst Abuse Treat       Date:  2012-01-28

Review 7.  Functional Neurocircuits and Neuroimaging Biomarkers of Tobacco Use Disorder.

Authors:  Matthew T Sutherland; Elliot A Stein
Journal:  Trends Mol Med       Date:  2018-02       Impact factor: 11.951

Review 8.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

9.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

Review 10.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.